Search

Author/Creator Hedrick, Eric

1. A real‐world study to assess the association of cardiovascular adverse events (CVAEs) with ibrutinib as first‐line (1L) treatment for patients with chronic lymphocytic leukaemia (CLL) in the United States. Issue 1 (23rd January 2023)

Authors:
Mato, Anthony; Tang, Boxiong; Azmi, Soraya; Yang, Keri; Han, Yi; Zhang, Xiaowei; Roeker, Lindsey; Wallis, Nicola; Stern, Jennifer C.; Hedrick, Eric; Huang, Jane; Sharman, Jeff P.
Journal:
EJHaem
Issue:
Volume 4:Issue 1(2023)
Page Start:
135
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Issue 5 (May 2018)

Authors:
Italiano, Antoine; Soria, Jean-Charles; Toulmonde, Maud; Michot, Jean-Marie; Lucchesi, Carlo; Varga, Andrea; Coindre, Jean-Michel; Blakemore, Stephen J; Clawson, Alicia; Suttle, Benjamin; McDonald, Alice A; Woodruff, Mark; Ribich, Scott; Hedrick, Eric; Keilhack, Heike; Thomson, Blythe; Owa, Takas...
Journal:
Lancet oncology
Issue:
Volume 19:Issue 5(2018)
Page Start:
649
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search